UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18

Benzinga Newsdesk www.benzinga.com Neutral 66.9%

Neg 0% Neu 66.9% Pos 0%

UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $18.